Plus, news about BenevolentAI, Adaptive Biotechnologies, Eisai, CNX Therapeutics, Vanda Pharmaceuticals and Nucleai:Ascletis Pharma ends liver disease program: The Chinese biotech will not pursue further development of ASC42 for primary biliary cholangitis after Phase 2 data suggested a lack of competitiveness versus competing candidates. Ascletis also dropped clinical work on the FXR agonist in hepatitis B. — Ayisha Sharma
Ascletis Announces Presentation of PII Final Results of FASN Inhibitor ASC40
Ascletis’ subsidiary Gannex revealed that its non-alcoholic steatohepatitis (NASH) drug candidate significantly reduced average levels of liver fat in patients enrolled in a mid-stage trial, marking a positive milestone for the Chinese company.
Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023